Advances in the treatment and prevention of severe viral bronchiolitis

Pediatric Annals

Volumn 34, Issue 1, 2005, Pages 35-41

  Domachowske, Joseph B ^a   Rosenberg, Helene F ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BRONCHODILATING AGENT; DEXTRAN SULFATE; DIACETYLTARTARIC ACID; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; LIVE VACCINE; NUCLEOSIDE; PALIVIZUMAB; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; RIBONUCLEASE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VEGETABLE PROTEIN; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ADENOVIRUS; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA; META ANALYSIS; MORTALITY; NONHUMAN; PATHOGENESIS; REVIEW; RHINOVIRUS; RNA VIRUS INFECTION; SEROPREVALENCE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRAL BRONCHIOLITIS;

EID: 12344279299     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20050101-10     Document Type: Review

References (33)

1. Shay DK, Holman RC, Newman RD, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446.
2. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis. 1994;18(5):770-779.
3. van den Hoogen BG, Osterhaus DM, Fouchier RA. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J. 2004;23(1 Suppl):S25-32.
4. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997;99(1):93-99.
5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-537.
6. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422-434.
7. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine. 2001;20(5-6):954-960.
8. Biacchesi S, Skiadopoulos MH, Tran KC, et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology. 2004;321(2):247-259.
9. Rodriguez WJ, Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 1987;6(2):159-163.
10. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325(1):24-29.
11. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983;72(5):613-618.
12. Wang EE, Law BJ, Boucher FD, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial lower respiratory tract infection. J Pediatr. 1996;129(3):390-395.
13. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J. 1993;12(3):209-213.
14. Barry W, Cockburn F, Cornall R, et al. Ribavirin aerosol for acute bronchiolitis. Arch Dis Child. 1985;61(6):593-597.
15. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection: a systematic overview. Arch Pediatr Adolesc Med. 1996;150(9):942-947.
16. Boeckh M, Berrey MM, Bowden RA, et al. Phase I evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184(3):350-354.
17. Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci. USA. 1996;93(5):2186-2191.
18. Leer JA Jr, Green JL, Heimlich EM, et al. Corticosteroid treatment in bronchiolitis. A controlled collaborative study in 297 infants and children. Am J Dis Child. 1969;117(5):495-503.
19. Dabbous IA, Tkachyk JS, Stamm SJ. A double blind study of the effects of corticosteroids in the treatment of bronchiolitis. Pediatrics. 1966;37(3):477-484.
20. Klassen TP, Sutcliffe T, Watters LK, et al. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. J Pediatr. 1997;130(2):191-196.
21. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R. Dexamethasone in bronchiolitis: a randomised, controlled trial. Lancet. 1996;348(9023):292-295.
22. De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double blind dexamethasone efficacy study. J Pediatr. 1997;131(6);919-921.
23. van Woensel JB, Wolfs TF, van Aalderen WM, Brand PL, Kimpen JL. Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax. 1997;52(7):634-637.
24. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics. 2000;105(4):E44.
25. Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis. 2002;185(9):1222-1228.
26. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996;15(1): 23-31.
27. Ottolini MG, Curtis SJ, Porter DD, et al. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother. 2002;46(7):2299-2302.
28. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16(3):393-399.
29. Easton AJ, Domachowske JB, Rosenberg HF. Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev. 2004;17(2):390-412.
30. Klassen TP, Craig WR, Moher D, et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. JAMA. 1998;279(20):1629-1632.
31. Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med. 1998;339(8):498-503.
32. Ausejo M, Saenz A, Pham B, et al. The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ. 1999;319(7210): 595-600.
33. Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of single dose of oral dexamethasone for mild croup. N Engl J Med. 2004;351(13):1306-1313.